About

About the Awards

Showcasing achievement and success in the UK and European healthcare, biotech, pharmaceutical and life sciences sectors

The European Mediscience Awards is now in its 22nd year, having been held every year since inception in 2002*. The event is the largest annual gathering of private and publicly quoted healthcare, biotech and life sciences companies in Europe. Bringing together the best of European mediscience companies to celebrate achievement and recognise success, it is the must-attend event for anybody working in this sector. 

Each year sees the attendance of over 500 quoted and private UK and European life sciences companies and their corporate advisers, analysts, fund managers, commentators and peers. The event is sold out from one year to the next.

The European Mediscience Awards 2024 will take place on Thursday 13 June at the Hotel InterContinental, London, W1.

*with the exception of 2020 when we were unable to hold a live event due to COVID-19, but instead held a successful digital campaign.  

 

Contact us

2023 showreel


View archive

Sponsors

Awards

covering the period 1 April 2023 to 31 March 2024

The Shortlist is announced

Shortlist

Click on each award to view more information

BEST COMMUNICATION AWARD

Sponsored by:

BREAKTHROUGH OF THE YEAR AWARD

Sponsored by:

BEST TECHNOLOGY AWARD

THE EMERGING STAR AWARD

Sponsored by:

MEDISCIENCE MEDIA COMMENTATOR OF THE YEAR AWARD

Sponsored by:

CAPITAL MARKET TRANSACTION OF THE YEAR AWARD

Sponsored by:

MOST SIGNIFICANT CONTRIBUTION TO THE MEDISCIENCE SECTOR AWARD

Sponsored by:

CHIEF EXECUTIVE OF THE YEAR AWARD

Sponsored by:

COMPANY OF THE YEAR AWARD

Sponsored by:

Voting panel

Meeting: Thursday 2 May 2024

Ian Restall_EMA24Judges_0003.jpg

Ian Restall

Ford Sinclair Ltd

(Voting panel Chairman)

Arron Aatkar_EMA24Judges_0001.jpg

Arron Aatkar

Edison Group

Mette Kirstine Agger_EMA24Judges_0004.jpg

Mette Kirstine Agger 

Esrum Biotech

Lisa Anson_EMA24Judges_0001.jpg

Lisa Anson

Redx Pharma plc

Hubert Birner_EMA24Judges_0005.jpg

Hubert Birner

TVM Capital

Tracy Cheung_EMA24Judges_0003.jpg

Tracy Cheung

ICR Consilium

Ailsa Craig _EMA24Judges_0004.jpg

Ailsa Craig

Schroders

Victoria Darbyshire_EMA24Judges_0002.jpg

Victoria Darbyshire

J.P. Morgan

John  Dawson_EMA24Judges_0003.jpg

John A. Dawson

Chris Donnellan_EMA24Judges_0002.jpg

Chris Donnellan

Cavendish

Liam Gascoigne-Cohen_EMA24Judges_0001.jpg

Liam Gascoigne-Cohen

SP Angel

Stefan Hamill_EMA24Judges_0003.jpg

Stefan Hamill

Hamill Life Sciences

Anne Hennecke_EMA24Judges_0003.jpg

Anne Hennecke

MC Services AG

Max Herrmann_EMA24Judges_0002.jpg

Max Herrmann

Stifel

Uli Kinzel_EMA24Judges_0004.jpg

Ulrich Kinzel

goetzpartners Securities Limited

Elena Lovo_EMA24Judges_0001.jpg

Elena Lovo

J.P. Morgan

Emily Pilkington_EMA24Judges_0003.jpg

Emily Pilkington

HSBC Innovation Banking

Tara Raveendran_EMA24Judges_0001.jpg

Tara Raveendran

Polar Capital

Craig Richardson_EMA24Judges_0004.jpg

Craig Richardson 

IP Group plc

Nick Rodgers_EMA24Judges_0003.jpg

Nick Rodgers

SEHTA

Julie Simmonds_EMA24Judges_0001.jpg

Julie Simmonds

Panmure Gordon

Tim Stamper_EMA24Judges_0003.jpg

Tim Stamper

FTI Consulting

Mark Swallow_EMA24Judges_0001.jpg

Mark Swallow

MEDiSTRAVA

Michael White_EMA24Judges_0001.jpg

Michael White

HSBC Innovation Banking

Ian Restall_EMA24Judges_0003.jpg

Ian Restall

Ford Sinclair Ltd(Voting panel Chairman)

Arron Aatkar_EMA24Judges_0001.jpg

Arron Aatkar

Edison Group

Mette Kirstine Agger_EMA24Judges_0004.jpg

Mette Kirstine Agger 

Esrum Biotech

Lisa Anson_EMA24Judges_0001.jpg

Lisa Anson

Redx Pharma plc

Hubert Birner_EMA24Judges_0005.jpg

Hubert Birner

TVM Capital

Tracy Cheung_EMA24Judges_0003.jpg

Tracy Cheung

ICR Consilium

Ailsa Craig _EMA24Judges_0004.jpg

Ailsa Craig

Schroders

Victoria Darbyshire_EMA24Judges_0002.jpg

Victoria Darbyshire

J.P. Morgan

John  Dawson_EMA24Judges_0003.jpg

John A. Dawson

Chris Donnellan_EMA24Judges_0002.jpg

Chris Donnellan

Cavendish

Liam Gascoigne-Cohen_EMA24Judges_0001.jpg

Liam Gascoigne-Cohen

SP Angel

Stefan Hamill_EMA24Judges_0003.jpg

Stefan Hamill

Hamill Life Sciences

Anne Hennecke_EMA24Judges_0003.jpg

Anne Hennecke

MC Services AG

Max Herrmann_EMA24Judges_0002.jpg

Max Herrmann

Stifel

Uli Kinzel_EMA24Judges_0004.jpg

Ulrich Kinzel

goetzpartners Securities Limited

Elena Lovo_EMA24Judges_0001.jpg

Elena Lovo

J.P. Morgan

Emily Pilkington_EMA24Judges_0003.jpg

Emily Pilkington

HSBC Innovation Banking

Tara Raveendran_EMA24Judges_0001.jpg

Tara Raveendran

Polar Capital

Craig Richardson_EMA24Judges_0004.jpg

Craig Richardson 

IP Group plc

Nick Rodgers_EMA24Judges_0003.jpg

Nick Rodgers

SEHTA

Julie Simmonds_EMA24Judges_0001.jpg

Julie Simmonds

Panmure Gordon

Tim Stamper_EMA24Judges_0003.jpg

Tim Stamper

FTI Consulting

Mark Swallow_EMA24Judges_0001.jpg

Mark Swallow

MEDiSTRAVA

Michael White_EMA24Judges_0001.jpg

Michael White

HSBC Innovation Banking

Ian Restall_EMA24Judges_0003.jpg

Ian Restall

Ford Sinclair Ltd(Voting panel Chairman)

Arron Aatkar_EMA24Judges_0001.jpg

Arron Aatkar

Edison Group

Mette Kirstine Agger_EMA24Judges_0004.jpg

Mette Kirstine Agger 

Esrum Biotech

Lisa Anson_EMA24Judges_0001.jpg

Lisa Anson

Redx Pharma plc

Hubert Birner_EMA24Judges_0005.jpg

Hubert Birner

TVM Capital

Tracy Cheung_EMA24Judges_0003.jpg

Tracy Cheung

ICR Consilium

Ailsa Craig _EMA24Judges_0004.jpg

Ailsa Craig

Schroders

Victoria Darbyshire_EMA24Judges_0002.jpg

Victoria Darbyshire

J.P. Morgan

John  Dawson_EMA24Judges_0003.jpg

John A. Dawson

Chris Donnellan_EMA24Judges_0002.jpg

Chris Donnellan

Cavendish

Liam Gascoigne-Cohen_EMA24Judges_0001.jpg

Liam Gascoigne-Cohen

SP Angel

Stefan Hamill_EMA24Judges_0003.jpg

Stefan Hamill

Hamill Life Sciences

Anne Hennecke_EMA24Judges_0003.jpg

Anne Hennecke

MC Services AG

Max Herrmann_EMA24Judges_0002.jpg

Max Herrmann

Stifel

Uli Kinzel_EMA24Judges_0004.jpg

Ulrich Kinzel

goetzpartners Securities Limited

Elena Lovo_EMA24Judges_0001.jpg

Elena Lovo

J.P. Morgan

Emily Pilkington_EMA24Judges_0003.jpg

Emily Pilkington

HSBC Innovation Banking

Tara Raveendran_EMA24Judges_0001.jpg

Tara Raveendran

Polar Capital

Craig Richardson_EMA24Judges_0004.jpg

Craig Richardson 

IP Group plc

Nick Rodgers_EMA24Judges_0003.jpg

Nick Rodgers

SEHTA

Julie Simmonds_EMA24Judges_0001.jpg

Julie Simmonds

Panmure Gordon

Tim Stamper_EMA24Judges_0003.jpg

Tim Stamper

FTI Consulting

Mark Swallow_EMA24Judges_0001.jpg

Mark Swallow

MEDiSTRAVA

Michael White_EMA24Judges_0001.jpg

Michael White

HSBC Innovation Banking

Shortlist review

Read more about this year’s shortlisted companies by selecting an award below.
Further award categories will be released shortly. 

Best Communication Award

sponsored by ICR Consilium

 
The 2024 shortlist:


EMA24-ShRvw_Comm_Hikma Pic+Logo.png

Hikma Pharmaceuticals plc

Headquartered in London, Hikma is a global company with a local presence across North America, the Middle East and North Africa (MENA) and Europe. The group provides a broad range of branded and non-branded generic medicines to bring innovative health technologies to people around the world. 

Hikma is a regular on the shortlist for the Best Communication Award and the team has continued to work hard to stay connected to all its stakeholders. Hikma has a targeted external communications programme to inform key audiences on its strategic progress, including organised investor roadshows in new markets across Europe and investor site visits at its Injectables manufacturing facility in Portugal. The group was commended for the strong communication of its succession planning/transition to the new CEO. 


EMA24-ShRvw_Comm_hVIVO Pic+Logo.png

hVIVO plc

London based hVIVO is a rapidly growing specialist contract research organisation, and a world leader in testing infectious and respiratory disease vaccines using human challenge clinical trials. The Group provides end-to-end early clinical development services to its large, established and growing repeat client base, which includes four of the top 10 largest global biopharma companies.

hVIVO has a strong and visible IR team that host a number of events for the investor community. The group’s clear and precise trading updates have led to a significant uplift in investor interest, resulting in continued growth in share price, despite challenging market conditions. hVIVO’s focus on investor relations and the growing interest from equity market participants is evidenced by the growing number of equity analysts providing research coverage on the group.


EMA24-ShRvw_Communic Moonlake Pic+Logo.png

MoonLake Immunotherapeutics

Based in Switzerland, MoonLake Immunotherapeutics is a clinical-stage biopharmaceutical company unlocking the potential of Sonelokimab, the novel investigational Nanobody® for the treatment of inflammation, to revolutionise outcomes for patients.

Last year was transformational for MoonLake Immunotherapeutics with several significant announcements, including landmark clinical trial results followed by a substantial fundraising. The group is heavily invested in communicating its pivotal achievements, hosting a large volume of R&D days and actively engaging with stakeholders and investors. The group has significantly increased its social media activity, resulting in a sharp rise in in followers and engagement.  


EMA24-ShRvw_Comm_Syncona Pic+Logo.png

Syncona Ltd

London-based Syncona is a leading healthcare company focused on creating, building and scaling a portfolio of global leaders in life science. The group focuses on developing treatments for patients by working in close partnership with world-class academic founders and management teams.

Syncona’s IR team has produced clear and definitive communications during the period, providing informative analysis and detail of its biotech portfolio, making it accessible and digestable to investors wanting access to the high growth biotech sector. The group recently expanded its senior investment team and evolved its operational model, which was well communicated to the market.


EMA24-ShRvw_Comm_tissue Regen Pic+Logo.png

Tissue Regenix Group plc

Leeds-based Tissue Regenix Group is a pioneering, international medical technology company, focusing on the development of regenerative products utilising its two platform technologies, dCELL®, addressing soft tissue needs, and BioRinse® providing sterile bone and soft tissue allografts.

Tissue Regenix enjoyed a solid year of growth, marked by completing several milestones, which were achieved following the implementation of a new strategy and new management team. The group’s consistently clear communication regarding its focused 4S strategy has helped drive Tissue Regenix’s growth and enabled the business to reach its next level of performance.


EMA24-ShRvw_Commu_Verona Pharma_Pic+Logo.png

Verona Pharma

Headquartered in London, Verona Pharma is a biopharmaceutical company focused on developing and commercialising innovative therapies for the treatment of chronic respiratory diseases. The group is developing ensifentrine, potentially the first treatment for respiratory disease that combines bronchodilator and anti-inflammatory activity in one compound.

Verona Pharma was commended by the Voting Panel for its outstanding communication efforts during a pivotal regulatory period. The group effectively used all available communication tools and made good use of social media around relevant national events such as Pulmonary Rehabilitation Week and National Doctors day. The IR team maintain regular, consistent dialogue with stakeholders.

Breakthrough of the Year Award

sponsored by FTI Consulting

 
The 2024 shortlist:


 

CRISPR Therapeutics AG

Based in Switzerland, CRISPR Therapeutics is a leading gene editing company with a strong and diversified pipeline. The group’s Nobel Prize-winning CRISPR science has revolutionised biomedical research and represents a powerful, clinically validated approach with the potential to create a new class of potentially transformative medicines.

Last year was a momentous year for CRISPR with multiple milestones achieved, including the remarkable breakthrough of the group’s first-ever approval of a CRISPR-based therapy. CRISPR’s product, CASGEVY, was approved in the US, EU, Great Britain, Bahrain, and the Kingdom of Saudi Arabia (KSA) for the treatment of patients with either sickle cell disease (SCD) or transfusion-dependent beta thalassemia (TDT). This historic achievement validates the group’s CRISPR/Cas9 gene-editing technology and paves the way for the future of gene-based medicines.


EMA24-ShRvw_Breakthru Kooth_transac Pic+Logo.png

Kooth plc

London-based and AIM-listed Kooth is a global leader in youth digital mental well-being. The group’s platform is clinically robust and accredited to provide a range of therapeutic support and interventions. All its services are predicated on easy access to make early intervention and prevention a reality.

2023 was a transformational year for Kooth, resulting in the group significantly expanding its services and capability. In July, Kooth signed the largest deal in its history, a $188m contract with the state of California to deliver behavioural health care to the State’s population of 13–25-year-olds. To support this contract, Kooth developed Soluna, a next-generation platform to help build mental health skills-for-life, access peer-support and professional help, which is offered for free to the State’s 6 million young people.


EMA24-ShRvw_Breakthru Newron Pic+Logo.png

Newron Pharmaceuticals SpA

Newron Pharmaceuticals is a biopharmaceutical company, based in Milan. The group is committed to delivering innovative treatments to improve the quality of life for patients with central nervous system (CNS) disorders.

In April this year, Newron announced positive top-line results from its potentially pivotal study evaluating the safety, tolerability and efficacy of evenamide in patients with chronic schizophrenia. The results of the trail were groundbreaking because this is the first major international study demonstrating the significant benefit of adding a new chemical entity (NCE) to poorly responding, compliant schizophrenia patients being treated with a second-generation antipsychotic. It is also the first demonstration of efficacy in a placebo-controlled trial of a NCE acting exclusively through glutamatergic inhibition.


EMA24-ShRvw_Santhera Pic+Logo.png

Santhera Pharmaceuticals

Based in Switzerland, Santhera is a speciality pharmaceutical company focused on the development of treatments for neuromuscular diseases currently lacking treatment options, such as Duchenne muscular dystrophy (DMD).

During the period, Santhera achieved various significant regulatory milestones for vamorolone, a first-in-class dissociative steroid which retains the anti-inflammatory activity of corticosteroids, while decreasing the deleterious side effects. Following these approvals, Santhera completed its first market launch of vamorolone in Germany in January 2024. Commercialisation of this product mean patients gain access to a treatment that overcomes the significant burdens associated with traditional steroid treatment.


EMA24-ShRvw_breakthru_valneva Pic+Logo.png

Valneva SE

Based in France, Valneva is a specialty vaccine company that develops, manufactures, and commercialises prophylactic vaccines for infectious diseases. The group has advanced a broad range of vaccine candidates into and through the clinic, including candidates against the chikungunya virus and Lyme disease.

In November last year, Valenva announced a significant breakthrough with the US FDA approval of IXCHIQ®, a single-dose, live-attenuated vaccine indicated for the prevention of a disease caused by chikungunya. Chikungunya is a mosquito-transmitted disease with potentially debilitating consequences. XCHIQ® is the world’s first licensed chikungunya vaccine available to address this unmet medical need and the third vaccine Valneva has brought from early R&D to approval.


EMA24-ShRvw_Breakthru_Zealand Pic+Logo.png

Zealand Pharma

Headquartered in Denmark, Zealand Pharma is a biotechnology company focused on the discovery and development of peptide-based medicines. More than 10 drug candidates invented by Zealand have advanced into clinical development, of which two have reached the market and three candidates are in late-stage development. 

Last year was transformational for Zealand Pharma as the group not only significantly advanced its obesity portfolio, but also delivered two regulatory submissions to the US FDA for its rare disease assets, resulting in a considerably strengthened financial position. Zealand’s collaboration with Boehringer Ingelheim reported positive Phase 2 results with survodutide in people living with overweight or obesity, leading to the initiation of a Phase 3 program, which could potentially position survodutide as a leading weight-loss medication in the future. 

Best Technology Award

 

 
The 2024 shortlist:


EMA24-ShRvw_Tech_4BaseBio Pic+Logo.png

4basebio AG

Headquartered in Germany and listed on AIM, 4basebio is an innovation-driven life biotech company focused on accelerating the development of advanced therapy medicinal products (ATMPs) through its high-performance synthetic DNA products and nonviral, cell targeting nucleic acid delivery platform.

4basebio has proprietary technology in the fields of DNA synthesis and payload delivery, enabling the group to manufacture both synthetic DNA constructs and mRNA and develop vectors for cell and tissue specific delivery for a range of applications. The technologies are unique because they are highly customisable, which significantly differentiates 4basebio’s offering and has resulted in increased commercial traction, in addition to a rise in share price.


EMA24-ShRvw_Avacta Pic+Logo.png

Avacta Group plc

Leeds based Avacta Group is focused on improving healthcare outcomes through targeted cancer treatments and diagnostics. The group has two divisions: a clinical stage oncology biotech division and a diagnostics division focused on supporting healthcare professionals.

Avacta’s pre|CISION™ platform is a highly specific substrate for fibroblast activation protein (FAP), which is upregulated in most solid tumours compared with healthy tissues. The platform enables targeted chemotherapy and increases tolerability, thereby enabling patients to benefit from what is still the mainstay of cancer treatment. Avacta recently announced encouraging clinical data from its lead pre|CISION™ peptide drug conjugate, which well positions the group for its evolution into a therapeutics-focused business.


EMA24-ShRvw_BiVictrix.png

BiVictriX Therapeutics plc

Cheshire-based BiVictriX is a rapidly emerging biotechnology company applying a novel approach to develop safer, more effective cancer therapies. Founded and led by a passionate and talented young female entrepreneur, the group is applying state of the art techniques to identify combinations of cancer-specific targets for both solid and liquid tumours. 

BiVictriX has developed Bi-Cygni® therapeutics, which are uniquely selective for particular cancer types, to enable higher dosing and more aggressive cancer eradication without causing harmful side effects. This approach allows the team to identify unique combinations of antigens that are present on the surface of cancer cells but not on healthy cells, which are then targeted with highly precise Antibody Drug Conjugates (ADCs). The ADC market is forecast to reach $23.9bn by 2032, making BiVictriX well-placed to take the lead in bringing forward the next generation of life-changing cancer treatments.


EMA24-ShRvw_Creo Pic+Logo.png

Creo Medical Group plc

Based in Chepstow, Creo Medical is an innovative and growing medical technology company. The group is transforming lives through the development and delivery of minimally invasive devices, by bringing Advanced Energy to the emerging field of therapeutic endoscopy.

Having developed a portfolio of innovative endoscopic instruments that can treat and potentially cure a range of cancers through minimally invasive treatments, Creo Medical is transitioning into a commercialisation company. The group has significantly expanded the user base of its lead device, Speedboat, which achieved a number of firsts through 2023, including the first upper gastrointestinal procedure performed in Europe. Initial health economic data has demonstrated that by using Creo’s technology, the NHS can save approximately £5,000 per procedure.


 

CRISPR Therapeutics AG

Switzerland-based CRISPR Therapeutics is a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases. The Nobel Prize-winning CRISPR science has revolutionised biomedical research and represents a powerful, clinically validated approach with the potential to create a new class of potentially transformative medicines.

CRISPR Therapeutics advanced the first-ever CRISPR/Cas9 gene-edited therapy into the clinic in 2018 to investigate the treatment of sickle cell disease or transfusion-dependent beta thalassemia. At the start of last year, the group announced its first-ever approval of a CRISPR-based therapy, with the approval of CASGEVY™ in the US, EU, Great Britain, Bahrain, and the Kingdom of Saudi Arabia. This historic achievement validates the group’s CRISPR/Cas9 gene-editing technology and paves the way for the future of gene-based medicines. 


EMA24-ShRvw_Maxcyte Pic+Logo.png

MaxCyte, Inc. 

Headquartered in the US and quoted on AIM, MaxCyte is a leading, cell-engineering focused company that enables platform technologies to advance innovative cell-based research as well as next-generation cell therapeutic discovery, development and commercialisation.

Maxcyte’s ExPERT™ platform, which is based on its Flow Electroporation technology, has been designed to support the rapidly expanding cell therapy market and can be utilised across the continuum of the high-growth cell therapy sector, from discovery and development through to commercialisation of next-generation, cell-based medicines. Last year, MaxCyte continued to advance its delivery technology with the launch of its VLx System, which revolutionises protein production with true scalability.

Mediscience Media Commentator of the Year Award

sponsored by MEDiSTRAVA

 
The 2024 shortlist:


EMA24-ShRvw_Biotech Hangout.png

Biotech Hangout

Biotech Hangout is a weekly discussion of all things biotech – breaking news, data, deals, and FDA actions – with a community of biotech industry leaders and experts. 

The show was conceived at the beginning of the COVID-19 pandemic when the team began gathering to discuss the latest industry news, as a way to stay connected, in lieu of in-person meetings. A tight knit community was created, which continued to convene every week, resulting in the weekly show which can be viewed live on X, with replays available on Spotify, Apple podcasts and on the show’s website. Biotech Hangout was founded by Chris Garabedian, Daphne Zohar and Brad Loncar, who has also been shortlisted for the European Mediscience Awards Media Commentator of the Year Award.


EMA24-ShRvw_S Hansen Comm Pic+Logo.png

Stephen Hansen/BioCentury

Stephen is BioCentury’s Associate Editor in the UK, where he serves as one of the group’s primary points of contact with European companies and investors. Stephen is renowned for his strong, robust articles on the biotech industry, which have earned him a regular place on the shortlist for the Mediscience Media Commentator of the Year.

Stephen has covered clinical development, corporate strategy and finance in Europe, the US and China for BioCentury for over a decade. He is a frequent contributor to BioCentury’s quarterly Financial Markets Preview and annual Buyside View and European Finance reports in addition to being a frequent contributor to, and occasional host, of BioCentury’s weekly podcast. 


EMA24-ShRvw_Hannah Kuchler FT Pic+Logo.png

Hannah Kuchler/Financial Times

Hannah has held the role of Global Pharmaceuticals Correspondent at the Financial Times for three years. She is an Emmy-nominated journalist with a flair for eye-catching stories and a commitment to accuracy and unbiased reporting. 

Hannah is a highly respected journalist who has covered a wide range of topics related to the pharmaceutical industry - including drug development, clinical trials, pricing, and access to medicines. Hannah led the FT side of a partnership with PBS Frontline to create the Opioids Inc documentary, which won a Loeb award, was nominated for an Emmy. In addition to her work for the Financial Times, Hannah has appeared on TV in NBC Bay Area's Press:Here show and featured on CNBC's Closing Bell, Sky News and the BBC World Service.


EMA24-ShRvw_Commentator_N_Loder.png

Natasha Loder/The Economist

Natasha Loder is The Economist’s health editor, covering a wide range of topics in medicine, technology, pharma and science. She has worked at The Economist since 2000, spending over a decade on the science desk.

Natasha is known for her strong commentary on key issues in healthcare and has won many awards for her work in news, features and opinion. In 2018, her feature about progress in cancer treatment won awards from the June L. Biedler Prize for Cancer Journalism, and the Medical Journalism Association. Natasha prides herself on her ability to turn dry science into thrilling stories and on bringing her passion and enthusiasm for her subjects to a wider audience.


EMA24-ShRvw_Biotech Pic+Logo.png

Brad Loncar/BiotechTV

BiotechTV brings the best of the biotech sector to life online. Founded by Brad, the website hosts news, stories, and educational videos about the biotechnology sector. 

BiotechTV hosts a hub of live content with key industry figures. Some of the site’s most recent content includes GSK's Emma Walmsley, who was interviewed by Brad on the company's pipeline, business development, AI, and the UK life sciences sector, in addition to Biotheryx's CEO being interviewed regarding the company's protein degradation platform. Biotech TV reports from key industry events, such as the recent JP Morgan Healthcare Week in San Franscisco, to update audiences on the latest technologies, innovations and breakthroughs in the world of biotech.


EMA24-ShRvw_Commentator_M Senior Pic+Logo.png

Melanie Senior 

Melanie is freelance journalist for Nature Biotech, Evaluate, Scrip and In Vivo. She demonstrates a profound understanding of the biotech sector and has a deep understanding of complex scientific concepts, making Melanie a regular on the shortlist for the Mediscience Media Commentator of the Year Award.

Melanie’s work has a significant impact on public understanding of biotech, especially around the developments of ADC's. She offers insightful analysis and commentary on biotech developments and landscape, including articles on new drug approvals and precision medicine. Melanie provides thought provoking perspectives on key issues within the industry and is engaging and witty with compelling story telling and narratives. 

The event


Sponsorship

Sponsorship opportunities sometimes become available, including sponsorship of an individual award, sponsorship of the official drinks reception or sponsorship of the menu. Sponsorship opportunities are, by their very nature, limited. Costs and availability on request.


Hosting a table

Reservations are available for tables of ten people. Numbers are strictly limited and reservations are taken on a first come, first served basis.


Advertising

Advertising in the digital brochure is welcomed and enables your key messages to reach a highly targeted audience. The digital event brochure is available to download on the night and contains details of the all nominees, the programme for the night and the menu. Uniquely, it also contains the names of all attendees, in alphabetical and table order. Thus it is widely used as  a reference post event for up to a year afterwards.


Bespoke sponsorship opportunities

We offer a range of bespoke sponsorship packages, tailor made to suit your marketing objectives and budget. Further information on request.


Enquiries

For all enquiries relating to the European Mediscience Awards, please do get in touch with jo.thomas@ford-sinclair.co.uk.

email us


Key details for guests

Date

Thursday 13 June 2024

Venue

Ballroom, Hotel InterContinental
One Hamilton Place
Park Lane
London W1J 7QY

Start time

6.00 p.m.   – Drinks reception 
7.30 p.m.   – Dinner 
9.15 p.m.   – Awards 
9.45 p.m.   – After-dinner entertainment 
12.00 midnight – Carriages 

Dress code

Black Tie

Charity collection

A charity collection will be taken up during the course of the evening and the European Mediscience Awards team will be available throughout to accept contactless donations. Thank you in advance for your generosity. 

 
Accommodation

 
Hotel InterContinental

A special rate of £355 for a single room and £380 for a double room per night inclusive of VAT and English breakfast has been secured for the night of the 13 June 2024, but is subject to availability. If you do wish to book a bedroom for the evening of the European Mediscience Awards, please use the link below, which is available until 20 May 2024.

book here

Location

Latest media

Charity

A charity collection will be held at the European Mediscience Awards 2024 and the total amount raised will be split equally between our two supported charities, BCCS and The Brain Tumour Charity.


 

BCCS provides highly professional and well‑supported Social Workers and Counsellors to help children and young people who are in need.

BCCS works in the East End of London and Essex with children, young people and their families and schools to help them overcome emotional difficulties, behavioural problems and their root causes. The prime focus of the work is to provide an early intervention service to enable them to address difficulties that may be impeding their educational, social and emotional development.

bccs.org.uk
@bccs_charity

 

The Brain Tumour Charity is the UK’s largest dedicated brain tumour charity, committed to fighting brain tumours on all fronts. It invests in pioneering research, in the UK and internationally, to increase survival and improve treatment options, and raises awareness of the symptoms of brain tumours to bring about earlier diagnosis.

It also offers a comprehensive support and information service for anyone who is affected by a brain tumour diagnosis, including a support and information line, Information Standard accredited fact sheets, online peer-to-peer support and a dedicated Children and Families Service.

thebraintumourcharity.org